Verrica Pharmaceuticals Announces YCANTH Data Readout Timelines and $15M Credit Facility
Verrica Pharmaceuticals (VRCA) reported record revenue for its YCANTH product for the second consecutive quarter during its Q3 2026 earnings update. The company is leveraging this commercial momentum to advance its clinical pipeline, specifically outlining upcoming data readouts for common warts expected in Q1 and mid-2027. To support ongoing operations and development, Verrica has secured a $15 million credit facility. This capital infusion provides the necessary liquidity to fund its commercial organization and continue progress through its late-stage clinical milestones.
Tickers: $VRCA